India Insulin Pumps Market By Type (Patch Pumps, Tethered Pumps), By End Use (Hospitals & Clinics, Homecare, Laboratories), By Region, Competition, Forecast & Opportunities, 2020-2030F

Market Overview

India Insulin Pumps Market was valued at USD 38.35 Million in 2024 and is expected to reach USD 64.39 Million by 2030 with a CAGR of 8.98% during the forecast period.

The India Insulin Pumps Market is experiencing steady growth, driven by the rising prevalence of diabetes, particularly Type 1 and insulin-dependent Type 2 cases, which are increasing due to sedentary lifestyles and unhealthy dietary habits. Urbanization and the growing awareness about advanced diabetes management solutions have further propelled the adoption of insulin pumps, especially in metro cities and South India, which dominate the market due to better healthcare infrastructure and a tech-savvy population. The convenience, precision, and technological advancements offered by insulin pumps, such as smartphone connectivity and continuous glucose monitoring (CGM) integration, have made them a preferred choice among patients seeking better glycemic control. Additionally, supportive government initiatives, such as awareness campaigns and diabetes care programs, along with the entry of multinational companies, have strengthened the market.

However, challenges such as the high upfront cost of insulin pumps, limited awareness in Tier 2 and rural areas, and a lack of adequate insurance coverage pose significant barriers to market growth. The dominance of tethered pumps highlights the cost sensitivity of the Indian population, even as patch pumps emerge as the fastest-growing segment due to their convenience and portability. Furthermore, the need for skilled endocrinologists and diabetes educators to train patients in using these devices effectively adds to the adoption hurdles, particularly in regions with inadequate healthcare infrastructure. Despite these challenges, the market is poised for expansion, driven by increasing awareness, improving affordability, and the growing focus on better diabetes management outcomes across the country.

Key Market Drivers

Increasing Prevalence of Diabetes

India’s rising diabetes burden is a major driver of the insulin pumps market. The WHO estimates ~77 million people currently live with diabetes in India, with nearly 25 million pre-diabetics, while the ICMR-INDIAB study reports 101 million diabetics and 136 million prediabetics around 57% undiagnosed. NFHS-5 shows 23% of women and 22.1% of men are overweight, with abdominal obesity at ~40% in women and 12% in men, reflecting lifestyle-driven risks.

Type 1 diabetes is also increasing, with the IDF Atlas estimating 300,788 children and adolescents (0-19 years) affected. ICMR’s Young Diabetes Registry, active since 2006 across 205 centres in 10 cities, highlights the growing need for precise insulin delivery. Diabetes complications including cardiovascular disease, retinopathy, nephropathy, and neuropathy are rising, reinforcing the importance of tight glycaemic control.

Government efforts such as 1,78,154 Ayushman Arogya Mandirs operationalized as of 15 July 2025 are strengthening screening and chronic care infrastructure. Together, escalating prevalence, high obesity rates, increasing pediatric Type 1 cases, and expanding healthcare access are accelerating adoption of insulin pumps, which offer continuous insulin delivery, reduced glycaemic variability, and improved quality of life—making diabetes prevalence a key growth driver for India’s insulin pumps market.

Rising Disposable Income

Rising disposable income in India is accelerating insulin pump adoption by improving affordability of advanced diabetes care. India’s per capita net national income increased from ₹1,35,050 in 2019-20 to ₹1,72,276 in 2022-23, and further to ₹1,84,205 in 2023-24, reflecting growing purchasing power, especially in urban and semi-urban areas.

Higher incomes enable patients to invest in premium solutions like insulin pumps and complementary technologies such as CGMs, despite their higher upfront costs compared to syringes or insulin pens. The expanding middle and upper-middle classes particularly in cities like Delhi, Mumbai, Bengaluru, and Hyderabad are increasingly prioritizing health, wellness, and convenient chronic disease management.

Greater financial capacity also improves access to private healthcare and awareness of advanced treatment options, while multinational manufacturers are meeting rising demand for premium devices. As income levels continue to improve, especially in Tier 1 cities, adoption of insulin pumps is expected to grow, reinforcing disposable income as a key driver of India’s technology-enabled diabetes care market.

Download Free Sample Report

Key Market Challenges

High Cost of Insulin Pumps

High device costs remain a major barrier to insulin pump adoption in India, especially among middle- and lower-income groups. MoHFW reimbursement guidelines under CGHS and CSMA Rules set ceiling prices at INR 2 lakh for basic pumps and INR 3 lakh for sensor-augmented pumps, with monthly consumables capped at INR 5,000 (reservoir, infusion set, insulin), highlighting both high upfront and recurring expenses.

Affordability is worsened by limited insurance coverage. National Health Accounts Estimates 2019-20 report household current health expenditure at INR 3,51,717 crore, with out-of-pocket spending remaining dominant. Clinical guidance also notes that insulin pumps in India are typically not reimbursed, requiring patients to self-fund both devices and consumables.

Restricted access to EMIs or medical loans and CGHS eligibility-linked reimbursement further exclude large population segments. Advanced options such as patch pumps face slower uptake due to higher total ownership costs, as reflected in differentiated pricing between basic and sensor-augmented pumps plus fixed consumable charges. These cost pressures significantly limit penetration in Tier 2 and Tier 3 cities, making high pricing a key challenge for India’s insulin pumps market.

Key Market Trends

Technological Advancements

Technological advancements are transforming India’s insulin pumps market by enabling more precise, personalized, and convenient diabetes management. Modern pumps now integrate CGMs, smartphone connectivity, and AI-driven algorithms to improve glycaemic control and the patient experience.

A key emerging trend is hybrid closed-loop (artificial pancreas) systems, which automatically adjust insulin delivery in real time using continuous glucose data, reducing hypoglycemia and hyperglycemia. Though still in early adoption in India, they signal a shift toward automation.

Smartphone app integration allows users and caregivers to track glucose levels, insulin delivery, and trends remotely benefiting young patients and working professionals seeking discreet, portable solutions. Devices are also becoming smaller, lighter, and more user-friendly, with patch pumps gaining traction for their tubeless, adhesive design, especially among active users and children, despite higher costs.

AI and machine learning are further enhancing pumps with predictive analytics that help anticipate glucose fluctuations based on diet, lifestyle, and activity. As awareness, availability, and affordability improve, these innovations are expected to remain a key growth trend, appealing to India’s tech-savvy and health-conscious diabetes population.

Segmental Insights

Type Insights

Based on Type, Patch Pumps have emerged as the dominating segment in the India insulin pumps market in 2024. Their rising adoption is fueled by the increasing demand for tubeless, discreet, and user-friendly insulin delivery systems, particularly among younger patients and those with active lifestyles. Technological advancements in wearable insulin pumps, coupled with growing awareness of automated insulin delivery solutions, have further strengthened their market position. Additionally, favorable reimbursement policies and the expanding diabetic population in India have contributed to the widespread acceptance of patch pumps, making them the preferred choice for insulin management.

End Use Insights

Based on End Use, Hospitals & Clinics have emerged as the fastest growing segment in the India Insulin Pumps Market during the forecast period. This growth was primarily fueled by the increasing role of hospitals and clinics in managing diabetes, from initial diagnosis to offering advanced treatment options such as insulin pump therapy. These healthcare facilities serve as the first point of contact for most diabetes patients, providing professional guidance on effective management strategies, including the use of modern technologies such as insulin pumps.

The presence of specialized diabetes care units and endocrinologists in hospitals has significantly contributed to this trend. Patients prefer hospitals and clinics for their expertise in selecting the right insulin pump model, ensuring proper device setup, and providing personalized training for effective use. Furthermore, hospitals actively monitor and provide follow-up consultations, which help patients maintain optimal glucose levels and enhance the overall experience of using insulin pumps.

Additionally, collaborations between hospitals and leading insulin pump manufacturers have facilitated increased accessibility to the latest products and technologies. Hospitals often organize awareness programs, workshops, and camps to educate patients about the benefits of insulin pump therapy, thereby further driving adoption.

Download Free Sample Report

Regional Insights

Based on Region, South India has emerged as the dominating region in the India Insulin Pumps Market in 2024, primarily due to its high prevalence of diabetes and better healthcare infrastructure. The region has a significant diabetic population, with states like Tamil Nadu, Karnataka, and Kerala reporting some of the highest diabetes rates in the country. This high disease burden drives the demand for advanced diabetes management solutions, including insulin pumps.

South India's dominance can also be attributed to its strong healthcare network and the availability of skilled endocrinologists and diabetologists, who are crucial in educating patients about the benefits of insulin pump therapy. Urban centers such as Bengaluru, Chennai, and Hyderabad are home to several leading hospitals and diabetes clinics, making insulin pumps more accessible to patients. These cities also have a higher concentration of individuals who can afford advanced medical devices, thanks to higher disposable incomes and a tech-savvy population.

The region also benefits from higher awareness of diabetes management than in other parts of the country. Various government initiatives and non-governmental programs focused on diabetes education have further contributed to the acceptance of insulin pump technology. Moreover, the adoption of innovative devices such as patch pumps and hybrid closed-loop systems is more prominent in South India, reflecting the population's willingness to invest in modern healthcare solutions.

Recent Development

• In Nov 2025, Renu MedTech’s own update positioned InsuPatch as Made-in-India and stated the device is currently under prototype development, with an affordability goal (targeted at ~1/10th of global cost) and design choices tuned for local climate/attire/lifestyle.
• In July 2025, the Nizam’s Institute of Medical Sciences (NIMS), in collaboration with the Endocrine Society of India (ESI), conducted a hands-on workshop to train young endocrinologists in the effective management of Type 1 diabetes through insulin pump therapy. A key highlight of the event was the state government’s initiative to provide insulin pumps free of cost to children diagnosed with Type 1 diabetes.
• In December 2024, Cipla has received approval for the distribution and marketing of inhaled insulin in India, marking a significant advancement in diabetes management. This innovative, needle-free alternative offers a convenient option for patients and improves adherence. Cipla’s entry into this segment is expected to enhance accessibility and revolutionize insulin delivery in India.
• In February 2024, Insulet's CE mark for integrating its Omnipod insulin pump with Abbott's Continuous Glucose Monitoring (CGM) system represents a significant advancement in diabetes care. This development, which enhances automated insulin delivery, has generated strong interest in India, spurring advanced diabetes management solutions and driving market growth.

Key Market Players

• Medtronic PLC
• Hoffmann-La Roche AG
• Ypsomed India Private Ltd
• Sanofi S.A.
• Ascensia Diabetes Care India

Report Scope

In this report, the India Insulin Pumps Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• India Insulin Pumps Market, By Type:

o   Patch Pumps

o   Tethered Pumps

• India Insulin Pumps Market, By End Use:

o   Hospitals & Clinics

o   Homecare

o   Laboratories

• India Insulin Pumps Market, By Region:

o   East India

o   West India

o   North India

o   South India

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the India Insulin Pumps Market.

Available Customizations:

India Insulin Pumps Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

India Insulin Pumps Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]